Artal Group S.A. lifted its position in AveXis Inc (NASDAQ:AVXS) by 25.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,000 shares of the company’s stock after buying an additional 30,000 shares during the period. Artal Group S.A.’s holdings in AveXis were worth $16,601,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of AveXis by 31.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares in the last quarter. State Street Corp increased its position in shares of AveXis by 104.2% in the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock valued at $64,923,000 after buying an additional 400,000 shares in the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in shares of AveXis in the 3rd quarter valued at $39,563,000. Institutional investors and hedge funds own 81.52% of the company’s stock.
In other news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $94.77, for a total transaction of $168,690.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $168,690.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $118.07, for a total transaction of $1,771,050.00. Following the transaction, the insider now owns 1,792,147 shares of the company’s stock, valued at $211,598,796.29. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,560 shares of company stock valued at $6,160,062. Company insiders own 18.60% of the company’s stock.
AveXis Inc (AVXS) opened at $116.55 on Friday. AveXis Inc has a 1-year low of $53.94 and a 1-year high of $128.00. The stock has a market capitalization of $4,235.95, a PE ratio of -20.89 and a beta of 2.10.
A number of research firms recently commented on AVXS. Royal Bank of Canada restated a “hold” rating and issued a $92.00 price objective on shares of AveXis in a research report on Thursday, November 2nd. Canaccord Genuity began coverage on shares of AveXis in a research report on Thursday, October 26th. They issued a “hold” rating and a $110.00 price objective for the company. Zacks Investment Research cut shares of AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. BidaskClub upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, Chardan Capital reiterated a “buy” rating and set a $135.00 target price on shares of AveXis in a report on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. AveXis presently has an average rating of “Buy” and an average target price of $116.95.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/avexis-inc-avxs-position-increased-by-artal-group-s-a.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc (NASDAQ:AVXS).
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.